The Safety and Efficacy of CD38 Monoclonal Antibody Monotherapy for CaAMR in Renal Transplantation
- Status
- UNKNOWN
- Phase
- NA
Clinical Trials Related to Daratumumab
Related studies linked through entity extraction aliases.
Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial
- Status
- RECRUITING
- Phase
- PHASE2
Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE2
Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Daratumumab-containing Induction Effects on Stem Cells Mobilization, colLection and Engraftment in Newly Diagnosed Multiple MyelomA Patients.
- Status
- COMPLETED
- Phase
- N/A
Efficacy of Daratumumab to Overcome Platelet Transfusion Refractoriness in Patients with Aplastic Anemia
- Status
- COMPLETED
- Phase
- PHASE1
Efficacy of Anti-CD20 Ab Associated With Anti-CD38 in the Childhood Multidrug Dependent and Resistant Nephrotic Syndrome
- Status
- RECRUITING
- Phase
- PHASE2
GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5
- Status
- RECRUITING
- Phase
- PHASE2
Daratumumab in Primary Antiphospholipid Syndrome
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Daratumumab for Treatment of Proliferative Glomerulonephritis With Monoclonal Immune Deposits
- Status
- RECRUITING
- Phase
- PHASE2
A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)
- Status
- TERMINATED
- Phase
- PHASE1
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
- Status
- RECRUITING
- Phase
- PHASE3
A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1/PHASE2
Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE2
A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE1
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE3
Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (ALTITUDE)
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2